- Johnson & Johnson (JNJ) plans to appeal a ruling by China's State Administration for Industry & Commerce (SAIC) to cancel the company's exclusive rights to the trademark for its OneTouch diabetes monitoring products.
- If upheld, SAIC's decision could pave the way for competitors to sell rival and cheaper products under the same name.
- China has around 100M diabetes sufferers, the largest number in the world.
- Separately, J&J has asked the FDA to require that biosimilars, which are copies of biological treatments, bear a similar but not identical name to reference therapies.
- In contrast, Novartis and Mylan want biosimilars to use the same international non-proprietary name.